NYSE$AMPE
Ampio Pharmaceuticals Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Announced financial results for the second quarter ended June 30, 2021.
Ampio Pharmaceuticals reported a net loss of $3.556 million for the second quarter of 2021. The company's cash and cash equivalents totaled $20.5 million as of June 30, 2021, compared to $17.3 million on December 31, 2020.
- Completed Phase I trial utilizing inhaled Ampion for COVID-19 patients with respiratory distress.
- Initiated Phase II trials utilizing inhaled Ampion and intravenous (IV) Ampion for COVID-19 patients with respiratory distress.
- Commenced enrollment for Phase II trials, expecting incremental increase as the inhaled Ampion Phase II study expands to India.
- Exploring the first at-home inhalation treatment for long COVID patients in a Phase I study utilizing inhaled Ampion.
Headline financials
Revenue & EPS history
Ampio · Revenue · Quarterly
$0
Forward guidance
Ampio expects to have sufficient funds to finance its operations through Q4 2022.
Tailwinds
- Cash and cash equivalents are expected to be sufficient.
- Access to external sources of liquidity is expected.
- Funding for research and development programs is expected.
- Funding for business operations is expected.
- Financial visibility through the fourth quarter of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
-0.4%
Avg return
Earnings day
-3.9%
Avg return
5 days after
-17.0%
Avg return
30 days after
31%
10 / 32 earnings
Positive
+32.5%
Q1 2011
Best reaction
-20.0%
Q4 2010
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2023 | +13.4% | -2.2% | -60.4% | |
| Q3 2023 | +6.2% | +0.1% | -21.1% | |
| Q2 2023 | +4.8% | -0.3% | +3.0% | |
| Q1 2023 | -8.3% | -8.9% | -3.5% | |
| Q4 2022 | +4.0% | -6.8% | -16.9% | |
| Q3 2022 | -18.9% | +8.1% | -25.8% | |
| Q3 2024 | -10.3% | -31.0% | -46.0% | |
| Q2 2022 | -9.1% | -4.5% | -15.9% | |
| Q1 2022 | +0.0% | -1.7% | -50.0% | |
| Q4 2021 | -8.0% | -7.7% | -57.2% | |
| Q3 2021 | -14.7% | -19.6% | -39.2% | |
| Q2 2021 | +9.8% | +13.6% | +28.8% | |
| Q1 2021 | +12.8% | +7.9% | -99.6% | |
| Q4 2020 | -5.5% | -10.9% | +12.1% | |
| Q3 2020 | +1.2% | -6.4% | +27.4% | |
| Q2 2020 | -1.9% | +0.9% | -30.4% | |
| Q1 2020 | +23.3% | +14.6% | +42.9% | |
| Q3 2019 | -7.7% | -7.3% | +7.1% | |
| Q1 2019 | +0.0% | -5.8% | +1.4% | |
| Q4 2018 | -8.8% | -16.2% | -24.7% | |
| Q3 2018 | -1.7% | -1.5% | -31.5% | |
| Q2 2018 | -2.1% | +0.6% | +26.3% | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q3 2012 | -4.7% | — | — | |
| Q1 2012 | -0.4% | — | — | |
| Q4 2011 | -2.6% | — | — | |
| Q3 2011 | -4.9% | — | — | |
| Q2 2011 | -1.3% | — | — | |
| Q1 2011 | +32.5% | — | — | |
| Q4 2010 | -20.0% | — | — | |
| Q3 2010 | -3.3% | — | — | |
| Q2 2010 | +27.3% | — | — | |
| Q1 2010 | -14.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro